We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Disease Diagnosis Based on Infrared Analysis of Blood Samples

By LabMedica International staff writers
Posted on 30 Mar 2021
Print article
Image: Blood panels are as individual as fingerprints. Investigators have now demonstrated that this so-called molecular fingerprint of the blood is stable over time (Photo courtesy of Max Planck Institute of Quantum Optics)
Image: Blood panels are as individual as fingerprints. Investigators have now demonstrated that this so-called molecular fingerprint of the blood is stable over time (Photo courtesy of Max Planck Institute of Quantum Optics)
A novel, infrared spectroscopy-based approach detects the status of a person’s health by monitoring changes in the molecular composition of blood samples.

Changes in an individuals health are reflected in characteristic modifications to the molecular composition of biofluids. Detecting these modifications could contribute to the detection of various disease states.

Toward this end, investigators at the Ludwig Maximilian University of Munich (Garching, Germany) and colleagues at the Max Planck Institute of Quantum Optics (Garching, Germany) used Fourier-transform infrared spectroscopy (FTIR) to “fingerprint” blood serum and plasma samples from healthy, non-symptomatic individuals.

The intent of the study was to address questions that are fundamental for the applicability of infrared fingerprinting in health monitoring, which means that the stability of the molecular patterns in healthy persons over time must be firmly established.

Initially, the investigators tested whether infrared spectral fingerprints could be obtained from bulk liquid blood serum and plasma samples in a direct and reproducible fashion. Then, they determined the range of natural biological variation of infrared fingerprints from individual volunteers over time (within-person variation). In addition, they related the variation of the IMFs over time for any given individual to the degree of variability between different individuals (between-person variation) and to operational variabilities inherent to clinical practice.

For this study, the investigators used FITR to fingerprint blood serum and plasma samples from 31 healthy, non-symptomatic individuals, who were sampled up to 13 times over a period of seven weeks and again after six months. The measurements were performed directly on liquid serum and plasma samples, yielding a time- and cost-effective workflow with a high degree of reproducibility.

Results revealed that the infrared molecular fingerprint of each individual donor remained stable over periods ranging from a few days to weeks and months, and that each temporal profile could be readily attributed to the participant concerned. Furthermore, single measurements yielded a multiplicity of person-specific spectral markers, allowing individual molecular phenotypes to be detected and followed over time.

"This newly revealed temporal stability of blood-based infrared fingerprints provides a basis for future applications of minimally invasive infrared spectroscopy as a reliable method for the future of health monitoring," said senior author Dr. Mihaela Žigman, head of the broadband infrared diagnostics group in the department of laser physics at the Ludwig Maximilian University of Munich. "Practically speaking, following-up a person's health status regularly might become paramount for timely-detecting relevant deviations. In addition to its uses in the fields of health monitoring and preventive medicine, systems biology shall also benefit from the availability of the approach."

The FITR study was published in the March 8, 2021, online edition of the journal Nature Communications.

Related Links:
Ludwig Maximilian University of Munich
Max Planck Institute of Quantum Optics


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.